Alembic Pharmaceuticals announces USFDA Tentative Approval for Selexipag for Injection, 1,800 mcg/vial

Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Uptravi® for Injection, 1,800 mcg/vial, of Actelion Pharmaceuticals US, Inc. (Actelion). Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Refer label for a detailed indication.

Based on the most recent update to the FDA's online paragraph IV database listings, Alembic is the sole first applicant to have filed its ANDA for Selexipag for Injection, 1,800 mcg/vial, containing a Paragraph IV certification under the provisions of the HatchWaxman Act. Upon final approval of this ANDA by USFDA, Alembic may be eligible for 180 days of generic marketing exclusivity in the U.S.

Alembic has a cumulative total of 208 ANDA approvals (180 final approvals and 28 tentative approvals) from USFDA.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 984.60 as compared to the previous close of Rs. 999.50. The total number of shares traded during the day was 10409 in over 1335 trades.

The stock hit an intraday high of Rs. 1012.15 and intraday low of 976.90. The net turnover during the day was Rs. 10307877.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 TentativeApproval ANDA USFDA Selexipag Injection